Teva Active Pharmaceutical Ingredients

Name

Teva Active Pharmaceutical Ingredients

Legal name

Teva Active Pharmaceutical Ingredients (TAPI)

Website

https://tapi.com

Company type

Private

Founded year

1935

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Teva Active Pharmaceutical Ingredients (TAPI) is the API manufacturing and bioprocessing division of Teva Pharmaceutical Industries Ltd., supplying active pharmaceutical ingredients and bioprocessing services to pharmaceutical companies developing metabolic, fibrotic, and other disease treatments globally.

Ownership category

akta.pro rank

Product category

Active Pharmaceutical Ingredients (API) Manufacturing

NAICS

Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro industry

PRIMARYHLAGAHAB

Small-Molecule API Commercial Manufacturing

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

SECONDARYHLAGAHAA

Small-Molecule API Process Development & Route Scouting

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

SECONDARYHLAGAHAL

GMP Scale-Up, Tech Transfer & Process Validation (PPQ)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

SECONDARYHLAIABAG

Generic APIs & Intermediates (Active Ingredients)

Healthcare & Life Sciences/Pharmaceuticals/Generic Pharmaceuticals

Keywords

• Active pharmaceutical ingredients
• API manufacturing services
• Bioprocessing capabilities
• Fixed-dose combinations
• Pharmaceutical contract manufacturing

Headquarters

HQ city

Tel Aviv

HQ country

Israel

HQ region

Middle East

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Technology or R&D, Personnel

Core offering

TAPI manufactures and supplies Active Pharmaceutical Ingredients (APIs), including Resmetirom API, and provides bioprocessing services through its European facilities to support pharmaceutical partners in scaling production. It also engages in fixed-dose combination (FDC) development, combining APIs such as resmetirom with other compounds for clinical programs targeting metabolic and fibrotic diseases such as MASH.

Product overview

Teva Active Pharmaceutical Ingredients (TAPI) operates as a pharmaceutical API manufacturer offering Active Pharmaceutical Ingredients and bioprocessing services. The company provides resmetirom API through licensing agreements and offers bioprocessing capabilities in Europe to support pharmaceutical ingredient production. TAPI's offerings include fixed-dose combination development services, combining APIs such as resmetirom with other compounds for clinical development programs targeting metabolic and fibrotic diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• Resmetirom API Active Pharmaceutical Ingredient (Resmetirom) licensed to Sagimet Biosciences for use in fixed-dose combination therapies combining resmetirom with Sagimet's denifanstat for Phase 3 trials targeting metabolic dysfunction-associated steatohepatitis (MASH).
• Bioprocessing Services Manufacturing and bioprocessing services delivered from TAPI's European facilities to enable pharmaceutical partners to scale up production of critical pharmaceutical ingredients and accelerate product launches.
• Fixed-Dose Combination (FDC) Development Program Fixed-dose combination development program combining Resmetirom API with Sagimet's denifanstat for Phase 3 clinical trials targeting metabolic dysfunction-associated steatohepatitis (MASH).

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• Sagimet BiosciencesStrategic or Co-development Partner · 17 December 2025Global license agreement for innovative forms of Resmetirom API for Sagimet's fixed-dose combination (FDC) program. The collaboration focuses on combining resmetirom with Sagimet's denifanstat for potential use in Phase 3 trials targeting metabolic dysfunction-associated steatohepatitis (MASH). Clinical trials are underway with topline data expected by end of 2025.
• AntheiacoreStrategic or Co-development Partner · 20 November 2025Strategic partnership to enhance production of pharmaceutical ingredients using TAPI's bioprocessing capabilities in Europe. The partnership aims to increase the scale and speed of Antheia's product launches, supporting its mission to end drug shortages.

Recent moves3 records

Expansion highlights3 records

Direct peers

• Sandoz (Novartis API / industrial business): Sandoz operates one of the largest generic API and finished-dose manufacturing networks globally and is a direct peer to TAPI as a large-scale, vertically integrated API supplier serving global pharma customers.
• Aurobindo Pharma: Aurobindo is a major Indian-headquartered producer of generic APIs and finished dosage forms, competing directly with TAPI in the global small-molecule API supply market, particularly for high-volume generics.
• Dr. Reddy's Laboratories (API business): Dr. Reddy's operates a substantial global API manufacturing and supply business across small molecules, overlapping with TAPI's commercial API offering to pharmaceutical customers.
• Sun Pharma (including Taro API operations): Sun Pharma is a top-tier Indian generic manufacturer with significant in-house API production for its own formulations and third-party supply, directly comparable to TAPI's role within Teva.
• Cipla: Cipla is a major global manufacturer of generic APIs and finished formulations, with broad small-molecule API capabilities comparable to TAPI's portfolio.
• Siegfried Holding: Siegfried is a Swiss-headquartered CDMO specializing in small-molecule API manufacturing and finished drug products, directly comparable to TAPI in scale, geography (Europe), and offering.
• EuroAPI: EuroAPI is a European-based, large-scale API manufacturer spun out of Sanofi, with a similar focus on small-molecule APIs and European bioprocessing — directly comparable to TAPI's European manufacturing footprint.
• Cambrex (Thermo Fisher Scientific CDMO business): Cambrex, now part of Thermo Fisher's CDMO segment, is a leading small-molecule API manufacturer and is directly comparable to TAPI in commercial API offerings and global customer base.
• Divi's Laboratories: Divi's is a major Indian-headquartered manufacturer of APIs and intermediates, with scale and process-development capabilities directly comparable to TAPI's commercial API operations.

Broad incumbents

• Lonza Group: Lonza is a global CDMO incumbent offering a broader portfolio (including biologics and cell & gene) with a small-molecule API and bioprocessing offering that overlaps with TAPI's capabilities, particularly in Europe.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/tapi---teva-active-pharmaceutical-ingredients

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Teva Active Pharmaceutical Ingredients